Trial Profile

BHV3000-401: An Open-label, Intermediate-size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rimegepant (Primary)
Indications Migraine
Focus Adverse reactions; Expanded access; Therapeutic Use
Sponsors Pfizer

Most Recent Events

26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
06 Jun 2021 Results assessing the safety and tolerability profiles and benefit from continued treatment with oral rimegepant 75 mg for the acute treatment of migraine, presented at the 63rd Annual Scientific Meeting of the American Headache Society.
28 Feb 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com